At the Company's AGM being held today at 2.30 pm the Chairman, Christopher Pearce, will make the following statement:

'As indicated in our recent results, we remain optimistic about the future, with the near-term availability of higher-plex TMT® set to add significant value to this asset, and the utility of quantitative proteomics increasing in response to diagnostic advances and disruptive technologies. We are pleased to report a good first quarter, with further growth in sales and royalties from TMT® and an improving services business continuing the trend in orders and revenues established during the latter part of 2018.'

View PDF Version

« Back To News

Attachments

  • Original document
  • Permalink

Disclaimer

Proteome Sciences plc published this content on 30 April 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 April 2019 16:37:02 UTC